Principal Financial Group Inc. Has $5.22 Million Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)

Principal Financial Group Inc. raised its stake in Schrödinger, Inc. (NASDAQ:SDGR) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 270,449 shares of the company’s stock after buying an additional 8,138 shares during the quarter. Principal Financial Group Inc. owned about 0.37% of Schrödinger worth $5,217,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Private Advisor Group LLC boosted its stake in Schrödinger by 20.5% in the 3rd quarter. Private Advisor Group LLC now owns 12,150 shares of the company’s stock worth $225,000 after purchasing an additional 2,065 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in shares of Schrödinger by 5.0% in the third quarter. Harbor Capital Advisors Inc. now owns 13,059 shares of the company’s stock valued at $242,000 after purchasing an additional 622 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Schrödinger by 1.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,191,054 shares of the company’s stock worth $40,644,000 after buying an additional 29,920 shares during the period. Pier 88 Investment Partners LLC grew its holdings in shares of Schrödinger by 83.6% during the third quarter. Pier 88 Investment Partners LLC now owns 77,130 shares of the company’s stock worth $1,431,000 after buying an additional 35,120 shares in the last quarter. Finally, KBC Group NV raised its position in Schrödinger by 45.4% in the 3rd quarter. KBC Group NV now owns 2,508 shares of the company’s stock valued at $47,000 after buying an additional 783 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Schrödinger Price Performance

Shares of SDGR opened at $21.24 on Tuesday. The firm has a 50-day moving average of $22.37 and a 200-day moving average of $20.62. The company has a market cap of $1.55 billion, a PE ratio of -9.08 and a beta of 1.61. Schrödinger, Inc. has a one year low of $16.67 and a one year high of $29.15.

Schrödinger (NASDAQ:SDGR) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The company had revenue of $88.32 million during the quarter, compared to analyst estimates of $83.20 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. Analysts expect that Schrödinger, Inc. will post -2.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SDGR. BMO Capital Markets upped their price target on Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Piper Sandler reduced their target price on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Finally, KeyCorp lifted their price target on shares of Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $32.29.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.